Ibrexafungerp

CAS: 1207753-03-4 F: C44H67N5O4 W: 730.03

Ibrexafungerp (MK 3118) is an orally active β-1,3-glucansynthesis inhibitor, with potential antifungal activity. Ibrexa

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Ibrexafungerp (MK 3118) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp can be used for research of Candida and Aspergillus infections[1].
Invitro	brexafunerp 对多种念珠菌 (Candida) 属具有抗真菌活性，MIC 为 0.5 µg/mL[2]。Ibrexafungerp 有效对抗 C. albicans, C. krusei, C. parapsilosis 感染，MIC 为 0.06、0.5、0.25 µg/mL[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ibrexafungerp 相关抗体:
In Vivo	Ibrexafunerp (口服，10 mg/kg) 可有效抵抗豚鼠皮肤梭状芽孢杆菌 (C. auris) 感染[4]。 Ibrexafungerp (口服，小鼠 1 mg/kg，大鼠 5 mg/kg 和狗 5 mg/kg) 表现出口服生物利用度 (小鼠 51%，大鼠 45%，狗 35%)[3]。Ibrexafungerp (尾静脉注射，小鼠 1 mg/kg，大鼠 5 mg/kg 和狗 5 mg/kg) 表现出血浆清除率高，半衰期适中 (小鼠 5.5、大鼠 8.7 和狗 9.3 小时)[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	1207753-03-4
Formula	C44H67N5O4
Molar Mass	730.03
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. James M Apgar, et al. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021 Jan 15;32:127661. [2]. Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9):539. [3]. Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16. [4]. Ghannoum M, et al. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00854-20. [5]. Arendrup MC, et al. In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02136-19.